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Introduction
In 1901, diabetes mellitus was described as “very 
uncommon” in Africa.1 Today, the situation is different. 
According to the International Diabetes Federation atlas, 
19.8 million people had diabetes in 2013 in Africa,2 and 
the number of patients is increasing. Diabetes in Africa is 
associated with a higher complication rate than that in 
developed countries, diabetes control parameters such 
as haemoglobin (Hb)A1c, blood pressure (BP) and lipids.3,4
Diabetic nephropathy is the major cause of end-stage 
renal disease (ESRD) in developed countries, i.e. ~ 30% 
of cases.5,6 In the near future, diabetic nephropathy is 
expected to become the most frequent cause of ESRD in 
the developing world.7 Approximately 20-30% of people 
with either type 1 or type 2 diabetes develop nephropathy, 
whose incidence increases with the duration of diabetes.5 
Certain ethnic groups, such as Native Americans, and 
Mexican and African Americans, demonstrate a higher 
prevalence rate of severe nephropathy in comparison to 
Caucasians.5,6 
The prevalence of diabetic nephropathy ranges from 
32-57% in Africa, and overt proteinuria is found in 5-28% 
of diabetic patients.3,8 Furthermore, diabetes mellitus 
contributes to a third of all patients in dialysis units in Africa.8 
Diabetic nephropathy is a major public health concern 
because dialysis and kidney transplantation therapy are 
almost completely inaccessible to most diabetic patients 
in Africa.9 Already, a 12-year follow-up study conducted 
in South Africa on a cohort of type 2 diabetic patients 
showed that ESRD was a major cause of death in 29% 
of the mainly non-Caucasian patients.10 Once a patient 
reaches the renal failure stage, therapeutic options are 
limited, given the severe shortage of dialysis slots in South 
Africa. Therefore, taking measures to prevent kidney 
disease is crucial. Early medical interventions and lifestyles 
changes, such as a reduction in protein intake and smoking 
cessation, have been shown to slow the progression from 
microalbuminuria to overt proteinuria, and eventually 
ESRD. Furthermore, there is impressive experimental and 
clinical evidence that angiotensin-converting enzyme 
(ACE) inhibitors have specific renoprotective properties in 
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Abstract
Objective: The aim of this study was to determine the prevalence of micro- or macroalbuminuria in type 1 and type 2 
diabetic patients, and to examine the relationship with the diabetes control parameters such as haemoglobin (Hb)A1c, 
blood pressure (BP) and lipids.
Design: This was an analytical cross-sectional study.
Setting and subjects: The study consisted of 754 patients with either type 1 or type 2 diabetes, attending a diabetes clinic 
at the Kalafong Hospital in Pretoria, South Africa. 
Outcome measures: Micro- or macroalbuminuria and estimated glomerular filtration rate (eGFR) were the outcome 
measures.
Results: An HbA1c > 7% was recorded in 88.9% of the patients, and low-density lipoprotein cholesterol ≥ 1.8 mmol/l in 81%. 
Overall, the prevalence of micro- or macroalbuminuria was 33.6%. Logistic regression revealed that HbA1c, the duration 
of diabetes, systolic BP, male sex and triglycerides were predictive of microalbuminuria.
Conclusion: The prevalence of micro- or macroalbuminuria in this study fell within the ranges of what has previously been 
reported in Africa. HbA1c and the duration of diabetes were the strongest predictors of microalbuminuria in all of the 
patients, and age was the strongest predictor of a low eGFR. Diabetes was poorly controlled, making the progression to 
end-stage renal failure a real concern in these patients.
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patients with diabetic or nondiabetic renal disease who 
have proteinuria.11 
The aim of this study was to determine the prevalence of 
diabetic nephropathy (micro- or macroalbuminuria) in 
type 1 and type 2 diabetic patients who attended the 
Kalafong Diabetes Clinic in Pretoria, and to examine 
the relationship between diabetes control parameters, 
including haemoglobin (Hb)A1, blood pressure (BP) 
levels, lipids and diabetic nephropathy in this group of 
predominantly African patients with diabetes.
Method
Study design
The study was an analytical cross-sectional study. 
Setting
The study was conducted at Kalafong Hospital, which is a 
tertiary public hospital in Pretoria, Gauteng, South Africa. 
The hospital serves as a training institution for the Faculty of 
Health Sciences of the University of Pretoria. Patients seen 
at the Kalafong Diabetes Clinic are usually referred on the 
basis of two criteria; either poorly controlled diabetes or 
BP, or the presence of diabetic complications.
Subjects  
Data were extracted from the electronic database of 
the Kalafong Diabetes Clinic on patients who attended 
the clinic from January to December 2012. Patients were 
excluded from the study if they were aged 18 years and 
younger, had either secondary or uncertain-type diabetes, 
or had nephropathy stemming from other causes. Patients 
were also excluded if they had only attended the clinic 
once in 2012, or if they had not had at least one or more 
of the following measurements performed: HbA1c, serum 
creatinine and urine albumin to creatinine ratio (ACR). 
Approval for the study was obtained from the Faculty of 
Health Sciences Research Ethics Committee, University of 
Pretoria (154/2013).
Measurements
Every patient who attends the Diabetes Clinic is scheduled 
for a minimum of four visits per year, i.e. one every three 
months. Kidney function is assessed biannually (ever six 
months) with a urine ACR on a random urine sample. 
HbA1c concentration and the serum concentrations of 
creatinine, total cholesterol, high-density lipoprotein (HDL) 
cholesterol and triglycerides are measured in peripheral 
blood, and low-density lipoprotein (LDL) cholesterol 
calculated using the Friedewald formula. All BP 
measurements were taken with an electronic BP machine 
(EDAN® Vital Signs Monitor, model M3A).
ACR: albumin to creatinine ratio, HbA1c: haemoglobin A1c
     
Figure 1: A flow chart of the patients included in our study
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Statistical analysis
Data were statistically analysed by means of Stata® version 
12 and SPSS® Statistics version 22. Descriptive statistics 
were carried out for all of the variables with appropriate 
methods, based on the type and distribution of the data. 
Frequency tables, cross-tabulation and the chi-square 
test were used. Logistic regression was performed to 
determine which predictor variables influenced the 
outcome.
Logistic regression was conducted as follows. Univariate 
logistic regression was carried out for the following 
variables: sex, race (dummy variables were created for 
black, white, Indian and coloured patients), age, type 
of diabetes, snuff use, smoking, body mass index (BMI), 
duration of diabetes, duration of hypertension, HbA1c, 
total cholesterol, LDL cholesterol, triglycerides, HDL 
cholesterol, mean systolic BP (SBP), mean diastolic BP 
(DBP), use of ACE inhibitors, the coefficients of variation in 
the SBP measurements and the coefficients of variation in 
the DBP measurements.
Variables with a p-value of more than 0.2 in a univariate 
analysis were excluded from the multivariable logistic 
regression. The analysis was consecutively performed, 
dropping variables from the preceding model that 
contributed the least to the overall performance of the 
model until the most parsimonious model was obtained, 
with the least number of predictor variables. 
The dependent variables were the estimated glomerular 
filtration rate (eGFR) < 60 ml/minute/1.73m2 (stage 2 
chronic kidney disease and higher) and microalbuminuria 
based on a urine ACR of more than 2.5 mg/mmol for males 
and 3.5 mg/mmol for females. The eGFR was calculated 
by using the Modification of Diet in Renal Disease (MDRD) 
study equation: eGFR (ml/minute/1.73m2)  = 186 × (serum 
creatinine)−1.154 × (age)−0.203 × (0.742, if female) × (1.212, if 
black).12 This multivariate analysis were performed for type 
1 and type 2 diabetic patients combined, and for both 
groups separately.
Results
The study population was the 798 diabetic patients who 
had attended the Kalafong Diabetic Clinic in 2012. On 
average, the number of visits attended per patient was 
4.09 (± 0.92) in 2012, ranging from 1-6 visits. Of all the 
patients, 44 were excluded. Eight were < 18 years old; 11 
made only one visit, or on whom information, such as their 
HbA1c, serum creatinine or urine ACR, was lacking; and 
25 had secondary diabetes, or the type of diabetes was 
uncertain (Figure 1). 
The demographic and clinical characteristics of the 754 
patients who fulfilled the inclusion criteria are outlined in 
Table I.
The patients were predominantly black (91.1%) and 
female (62.9%), with a mean age of 57.2 (± 14.9) years. 
The majority of the 754 patients (66.6%) had type 2 
diabetes. The median duration of diabetes was 11 years. 
Most patients (71.8%) had never smoked, and 10.5% 
Table I: The clinical characteristics of the diabetic patients who 
attended the Kalafong Diabetic Clinic in Pretoria in 2012
Characteristics N = 754
n (%)* 











Type 1 252 (33.4)
Type 2 502 (66.6)
Duration of diabetes Range of 0-64 years, median of  










Body mass index (kg/m2) n = 734, mean of 31.5, standard 
deviation 6.7
Underweight: < 18.5 8 (1.0)
Normal: 18.5-25 107 (14.6)
Overweight: 25-30 214 (29.2)
Obese (class 1): 30-35 199 (27.1)
Obese (class 2): 35-40 129 (17.6)
Obese (class 3): (> 40) 77 (10.5)
Hypertension** 597 (79.2)
Unknown 2 (0.3)
Duration of hypertension n = 595, range of 0-62 years, median 
of 11 years (interquartile range of 
7-18)
ACE inhibitor use 566 (75.1)
ACE: angiotensin-converting enzyme
*unless stated otherwise
**hypertension of > 140 mmHg systolic blood pressure and/or 90 mmHg diastolic 
blood pressure
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were current smokers at the time of the data collection. 
The majority of the patients (84.4%) were classified as 
overweight and obese, with a mean BMI of 31.5 kg/m2 
(± 6.7 kg/m2). High BP was diagnosed in 79.2% of the 
patients, of whom 75.1% were receiving ACE inhibitors.
Patients were compared according to their type of 
diabetes (Table II). As expected, the type 1 patients were 
significantly younger than the type 2 patients (mean age 
46.5 vs. 62.6 years, p-value < 0.001), had a shorter known 
duration of diabetes (11.4 vs. 13.4 years), (p-value 0.003), 
and with lower frequencies of hypertensive disease (57.1% 
vs. 90.2%) (p-value < 0.001).
Evaluation of diabetes control parameters: haemoglobin 
A1c, blood pressure and lipids
The HbA1c of the patients ranged from 5.4-22.5%, with a 
median of 9.6%. The mean SBP was 140.4 mmHg (± 16.9 
mmHg), and the mean DBP 80.9 mmHg (± 9.8 mmHg). The 
medians for total cholesterol, triglycerides and LDL were 
4.4, 1.4 and 2.5 mmol/l, respectively (Table III).
Table III: Diabetes control parameters
Variables n Statistics
HbA1c (%) 745 Range 5.4-22.5
Median 9.6 (IQ 7.8-11.8)
BP (mmHg) 
SBP* 754 Mean 140.4, SD 16.9
DBP** Mean 80.9, SD 9.8
Lipids (mmol/l)
Total cholesterol 706 Median 4.4
Triglycerides 702 Median 1.4
LDL*** 690 Median 2.5
DBP: diastolic blood pressure, HbA1c: haemoglobin A1c, IQ: interquartile range, LDL: 
low-density lipoprotein, SBP: systolic blood pressure, SD: standard deviation 
*Systolic blood pressure: Good (< 140 mmHg), moderate (140-160 mmHg) and poor 
(> 160 mmHg)
**Diastolic blood pressure: Good (< 80 mmHg), moderate (80-100 mmHg) and poor 
(> 100 mmHg)
***Low-density lipoprotein was calculated using the Friedewald formula. Low-
density lipoprotein could not be calculated in a number of patients with very high 
triglycerides
A small proportion of the study population (11.1%) met the 
HbA1c target (HbA1c < 7%), i.e. 13.8% of the type 1, and 9.8% 
of the type 2 patients. An HbA1c of over 10% was recorded 
in roughly half of the type 1 patients (50.4%). More than 
66% of the type 1 patients had a good SBP, against 49.2% 
of the type 2 patients. Most patients (96.2%) had a DBP of 
less than 100 mmHg. All of them had relatively good total 
cholesterol and triglycerides levels, but 79.5% of them had 
LDL levels ≥ 1.8 mmol/l.
Assessment of the renal function of patients: urine 
albumin to creatinine ratio and estimated glomerular 
filtration rate
The results of urine ACR and eGFR are given in Table IV.
Table IV: The assessment of renal function using estimated 
glomerular filtration rate and the urine albumin to creatinine 
ratio
Variables n (%)*
Urine ACR (mg/mmol) n = 735, range 0.0-977.0,
median 1.3 (IQ: 0.6-5.6)
Normal: < 2.5 (male) and 3.5 
(female)
488 (66.4)
Microalbuminuria: 2.5-25 (male) 
and 3.5-35 (female)
169 (23.0)
Macroalbuminuria: > 25 (male) 




n = 721, range 1.9-430.5,
median 102.3 (IQ 71.4-138.9)
> 60 ml/minute/1.73m2 721 (82.7)
< 60 ml/minute/1.73m2 721 (17.3)
ACR: albumin to creatinine ratio, eGFR: estimated glomerular filtration rate, IQ: 
interquartile range, MDRD: Modification of Diet in Renal Disease (study)
* unless stated otherwise
Of the study population, 66.4% had a normal urine 
ACR, meaning less than 2.5 mg/mmol for males and 
3.5 mg/mmol for females. The median recorded urine 
Table II: Description of the study population according to the 
type of diabetes
Characteristics Type 1, n = 252
n (%)
Type 2, n = 502
n (%)
p-value
Age in years, mean 
(SD)
46.5 (15.6) 62.6 (11.3) < 0.001
Gender 
Male 122 (48.4) 158 (31.5) < 0.001
Female 130 (51.6) 344 (68.5)
Race                 
Black 235 (93.3) 452 (90) 0.001
White 14 (5.6) 13 (2.6)
Coloured 0 (0.0) 3 (0.6)
Indian 3 (1.2) 34 (6.8)
Smoking status
Current 36 (14.3) 43 (8.6) 0.08
Never 169 (67) 372 (74.1)
Stopped 46 (18.3) 84 (16.7)
Unknown 1 (0.4) 3 (0.6)
Snuff use 17 (6.8) 45 (9) 0.121
Unknown 13 (5.2) 13 (2.6)
Duration of 
diabetes (in years), 
mean (SD)
11.4 (8.3) 13.4 (8.4) 0.003
Body mass index, 
mean (SD)
29.3 (6.5) 32.5 (6.5) < 0.001
Hypertension 144 (57.1) 453 (90.2) < 0.001




11 (8) 14.2 (9) < 0.001
ACE inhibitor use 169 (67.1) 397 (79.1) < 0.001
ACE: angiotensin-converting enzyme, SD: standard deviation
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ACR for both sexes was 1.3 mg/mmol. The prevalence 
of microalbuminuria was 23%. The eGFR of the patients 
using the MDRD formula ranged from 1.99-430.5, with a 
median of 102.3 ml/minute/1.73m2. A low eGFR (< 60 ml/
minute/1.73 m2) was recorded in 17.3% of the patients. 
Logistic regression analysis
Logistic regression analysis was conducted to determine 
which predictor variables influenced the outcome, i.e. 
microalbuminuria (urine ACR) and low eGFR (< 60 ml/
minute/1.73 m2) in all patients, then in the type 1 patients 
only, and finally in the type 2 patients only.
The prediction success achieved for microalbuminuria 
in all of the patients was 75.1%, with a model chi-square 
of 146.9 (p-value < 0.001). The variables of SBP (p-value 
< 0.001), HbA1c (p-value < 0.001), duration of diabetes 
(p-value < 0.001), triglycerides (p-value 0.008) and male 
sex (p-value < 0.001) made a significant contribution to 
the prediction. Thus, if the values of SBP, HbA1c, duration 
of diabetes and triglycerides were raised by one unit, 
the odds of obtaining microalbuminuria would be more 
likely to increase. The use of ACE inhibitors did not seem 
to have an influence on microalbuminuria as measured 
by the urine ACR.
The prediction success for eGFR in all of the patients was 
69%. A test of the full model against a constant-only model 
was statistically significant, indicating that the predictors, 
as a set, reliably distinguished between diabetic patients 
with an eGFR < 60 ml/minute/1.73m2 and the others (chi-
square 122.5, p-value < 0.001). Nagelkerke’s R2 of 0.213 
indicated a moderate relationship between prediction 
and grouping. The independent variables that contributed 
significantly to the prediction were age (p-value < 0.001), 
duration of hypertension (p-value 0.022) and being Indian 
(p-value 0.005). It should be noted that an unexpected 
difference was demonstrated for the predictors of urine 
ACR and eGFR. There was a small number of Indian 
patients in the study. Despite this small number, this was 
still a significant predictor of lower eGFR in this subset of 
patients.
A logistic regression analysis was conducted to predict 
microalbuminuria in type 1 diabetic patients only. A value 
of 49.6 (p-value < 0.001) was reported for the model 
chi-square. The Hosmer-Lemeshow (H-L) goodness-of-fit 
test statistic was greater than 0.05. Therefore, the model 
was quite a good fit. HbA1c (p-value < 0.001), duration 
of diabetes (p-value < 0.001) and triglycerides (p-value 
< 0.001) contributed significantly to the model. The use of 
ACE inhibitors seemed to play a nonsignificant protective 
role in this model.
The prediction success for eGFR worse than stage 1 
was 79.3%. The H-L goodness-of-fit test was 0.055, which 
means that the estimate of the model fitted the data at 
an acceptable level. Age (p-value < 0.001), SBP (p-value 
0.022) and coefficient variation of DBP (p-value 0.008) 
significantly contributed to the model.
Finally, logistic regression analysis to predict eGFR < 60 ml/
minute/1.73 m2 and microalbuminuria in type 2 patients 
was conducted. Overall, the prediction success was 73% 
and 65% for microalbuminuria and eGFR, respectively.
HbA1c (p-value < 0.001), the duration of diabetes (p-value 
< 0.001), SBP (p-value < 0.001), male sex (p-value < 0.001) 
and ACE inhibitors (p-value 0.025) were the independent 
variables that contributed significantly to the prediction 
of microalbuminuria in the patients with type 2 diabetes 
mellitus. According to the model, the use of ACE inhibitors 
was negatively associated with microalbuminuria, and 
thus protective [odds ratio (OR) 0.558, 95% confidence 
interval (CI): 0.336-0.928].
Age (p-value < 0.001) and Indian descent (p-value 
0.008) wee the independent variables that seemed to 
have made a significant contribution to the prediction of 
eGFR. It seems that from the abovementioned models, 
protection relating to Indian descent with regard to 
eGFR was only valid in type 2 diabetic patients, probably 
because there were very few Indian patients with type 1 
diabetes.
Discussion
This analytic cross-sectional study, using a study population 
of 798 diabetic patients attending a tertiary care diabetes 
clinic in Pretoria, provided the opportunity of determining 
the prevalence of micro- or macroalbuminuria, and of 
examining the relationship between microalbuminuria 
and putative risk factors.
Glycaemic control, as measured by the HbA1c, was 
poor. More than 88% of the patients did not meet the 
HbA1c target of < 7%, as recommended by the 2012 
South African Society for Metabolism, Diabetes and 
Endocrinology (SEMDSA) guidelines. Webb et al found 
that more than 70% of patients had an HbA1c value > 7% 
in a cluster randomised trial conducted in the Tshwane 
district.13 73.8% of patients failed to meet the HbA1c target 
in another study conducted in a South African population 
with type 2 diabetes.14 Poor glycaemic control has also 
been reported in other parts of sub-Saharan Africa, 
i.e. South Africa (Cape Town), Northern Ethiopia and 
Kenya.15-17 
Lipid control was poor, with an LDL cholesterol value 
> 1.8 mmol/l  in 81% of the patients. Webb et al reported 
similar results. There were uncontrolled lipids in more than 
80% of their study population.13 
In this study, the mean SBP was 140 mmHg and the mean 
DBP 80 mmHg. More than half of the patients (54%) had 
a DBP above the target recommended by the 2012 
SEMDSA guidelines. Webb et al reported a slightly higher 
mean SBP and mean DBP of 143 mmHg and 85 mmHg, 
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respectively.13 However, Gill et al recorded a lower mean 
SBP (108 mmHg) and mean DBP (72 mmHg) than that in 
this study.16 
In the present study, 84.4% of the patients were overweight, 
including 55.2% who were obese. Webb et al found similar 
levels of obesity in their study, where more than 80% of 
patients were overweight.13 
One of the limitations of the present study was that it was 
a tertiary, clinic-based study. The study population was 
mostly patients who were difficult to control at a lower level 
of care, and who were therefore referred to the tertiary 
clinic. This difference in the patient population might have 
introduced some degree of referral bias, making it difficult 
to extrapolate the results to the general population or 
to primary healthcare diabetes management. However, 
diabetes control was also shown to be suboptimal in two 
other studies conducted in South Africa.13,14 The first study 
was on diabetic patients attending primary healthcare 
clinics, but the study population from the second study 
presented at a diabetic clinic in a tertiary academic 
hospital similar to ours, after being referred by their treating 
physicians at the primary clinics.13,14 
The prevalence of micro- or macroalbuminuria in 
patients with type 1 and type 2 diabetes was 33.6%; 23% 
for microalbuminuria and 10.6% for macroalbuminuria, 
in this cross-sectional analysis. In other studies, various 
frequencies of microalbuminuria have been found, 
ranging from 10.7-39%.18-22 This variation in the frequency 
of microalbuminuria may be attributed to different 
factors, such as method of urine collection, differences 
in the population and sample sizes, ethnic susceptibility 
to develop nephropathy, as well as differing definitions of 
microalbuminuria. 
A statistically significant relationship between 
microalbuminuria and both poor glycaemic control 
(HbA1c) and duration of diabetes was shown in our study. 
This result was consistent when type 1 and type 2 diabetic 
patients were both included in the logistic regression 
models, but also when analysed separately.
Poor glycaemic control is a well-defined contributor to 
the development and progression of microalbuminuria 
in diabetic patients. Ghosh et al found that HbA1c was 
strongly associated with microalbuminuria.21 However, 
Lutale et al failed to demonstrate any significant 
relationship between the level of glycaemic control and 
microalbuminuria in a population of type 1 and type 2 
diabetic patients in Tanzania.22 
Ghosh et al could not demonstrate a significant 
correlation between microalbuminuria and the duration 
of diabetes, in contrast to our study.21 These authors 
suggest that the absence of a significant correlation 
between microalbuminuria and diabetes duration could 
be owing to the difficulty in dating the onset of diabetes. 
High BP is known to be the most significant contributing 
factor to the development of diabetic nephropathy 
in both type 1 and type 2 diabetic patients.22 In the 
current study, SBP was significantly associated with 
microalbuminuria in type 2 diabetic patients, and also 
when type 1 and type 2 diabetic patients were combined 
in the predictive model. Similar results were found in two 
studies conducted in Tanzania in 2007 and 2012, as well 
as in a cohort of African patients with type 1 diabetes in 
South Africa.21-23 
Triglycerides significantly correlated with microalbuminuria 
in logistic regression models for the type 1 and type 
2 patients combined, and for the type 1 diabetic 
patients only. Male sex was significantly predictive of 
microalbuminuria in logistic models for all of the diabetic 
patients and for the type 2 diabetic subjects only. Male 
sex has previously been found to be associated with a 
high risk of nephropathy in type 2 diabetic patients.11 
Although 10.5% of the patients were currently smoking, 
smoking was not predictive of either microalbuminuria 
or a reduced eGFR in this study. The failure to provide 
evidence that confirmed smoking as a predictor of 
diabetic nephropathy could be explained by the low 
prevalence of smoking in the study population. Parving 
et al, who analysed a study population of 32 208 type 2 
diabetic patients, found an association between micro- 
and macroalbuminuria and smoking (OR 1.15, 95% 
CI: 1.08-1.22).19
The use of ACE inhibitors seemed to play a protective 
role in type 2 diabetic patients in the current study, yet 
nonsignificantly in type 1 diabetic patients. Seventy-
five per cent of the study population were on ACE 
inhibitors. The only times that patients attending the 
Kalafong Diabetes Clinic were not given ACE inhibitors 
were when they could not tolerate the medicine, if 
they had significant side-effects therefrom, and when 
they had a normal BP without microalbuminuria. This 
may have contributed to confounding by indication 
or contraindication. ACE inhibitor use is not commonly 
reported in studies on diabetic nephropathy in African 
patients. In the study by Pinchevsky et al, 80% of the 
patients were on ACE inhibitors.14 Ghosh et al found 
that hypertensive patients who were on ACE inhibitors 
or angiotensin-receptor blockers were three times more 
likely to have normoalbuminuria than those using other 
antihypertensive medications.21 
The median eGFR was 102.3 ml/minute/1.73 m2, and 17% 
of the patients had more than stage 1 renal insufficiency 
(eGFR < 60 ml/minute/1.73 m2). These results are similar to 
those found in a cross-sectional study in which diabetic 
patients from 33 countries were evaluated, where the 
authors reported that eGFR was below 60 ml/minute/ 
1.73 m2 in 22% of the patients.19 
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In this study, a low eGFR (< 60 ml/minute/1.73 m2) was 
significantly associated with age in all of the models. Indian 
race was predictive of a lower eGFR. However, there was 
a small number of patients of Indian descent in the study. 
Despite this, it was still a significant predictor of lower eGFR 
in this subset of patients. This may be explained by the fact 
that patients of Indian decent have a lower muscle mass, 
which could explain the lower eGFR.24 
Micro- or macroalbuminuria were not always confirmed 
by two urine specimens in the present study, contrary 
to most recommendations. However, a similar method 
has been used in other settings.19,20 The size of the study 
population was a strength in this study. 
Conclusion
The prevalence of micro- or macroalbuminuria in our study 
fell within the range of what has previously been reported 
in sub-Saharan Africa. HbA1c and duration of diabetes 
were the strongest predictors of microalbuminuria in 
all of the patients, and age was the strongest predictor 
of a low eGFR. Diabetes was poorly controlled, making 
the progression to ESRD a real concern in those patients. 
Therefore, focus must be placed on measures to prevent 
the progression of renal lesions, i.e. strict glycaemic 
control, smoking cessation, the attainment of an optimal 
BP, the initiation of lipid-lowering therapy, and attempts to 
decrease urinary albumin excretion.
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